BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Aripiprazole (Abilify) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Aripiprazole (Abilify)\, from ClinicalTri
 als.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05814640-9212@assetmemo.bio
DTSTAMP:20261121T005405Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Aripiprazole (Abilify): Phase 1/2 readout est. (NCT05814640)
DESCRIPTION:Aripiprazole (Abilify)\, phase 1/2.\nStudy: Sequenced Treatment
  Alternatives to Relieve Adolescent Depression (STAR-AD)\nEstimated primar
 y completion: 31 December 2026. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/aripiprazole-abilify#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05814640
URL:https://assetmemo.bio/drug/aripiprazole-abilify#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07011693-9212@assetmemo.bio
DTSTAMP:20261121T005405Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Aripiprazole (Abilify): Phase 4 readout est. (NCT07011693)
DESCRIPTION:Aripiprazole (Abilify)\, phase 4\, Major Depressive Disorder.\n
 Study: Switching Medication and Augmentation Strategies for SSRI-Resistant
  Adolescent Depression（SMART-I)\nEstimated primary completion: June 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/aripiprazole-abilif
 y#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 011693
URL:https://assetmemo.bio/drug/aripiprazole-abilify#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07215884-9212@assetmemo.bio
DTSTAMP:20261121T005405Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Aripiprazole (Abilify): Phase 1 readout est. (NCT07215884)
DESCRIPTION:Aripiprazole (Abilify)\, phase 1.\nStudy: Dopamine and Sensorim
 otor Function in Stuttering\nEstimated primary completion: 30 June 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/aripiprazole-abilify#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07215
 884
URL:https://assetmemo.bio/drug/aripiprazole-abilify#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04539951-9212@assetmemo.bio
DTSTAMP:20261121T005405Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Aripiprazole (Abilify): Phase 2 readout est. (NCT04539951)
DESCRIPTION:Aripiprazole (Abilify)\, phase 2.\nStudy: Pragmatic Trial of Ob
 sessive-compulsive Disorder\nEstimated primary completion: 30 June 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/aripiprazole-abilify#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04539
 951
URL:https://assetmemo.bio/drug/aripiprazole-abilify#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05545891-9212@assetmemo.bio
DTSTAMP:20261121T005405Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Aripiprazole (Abilify): Phase 2 readout est. (NCT05545891)
DESCRIPTION:Aripiprazole (Abilify)\, phase 2.\nStudy: Aripiprazole in Body 
 Focused Repetitive Behaviors\nEstimated primary completion: December 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/aripiprazole-abilify
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT055
 45891
URL:https://assetmemo.bio/drug/aripiprazole-abilify#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07714213-9212@assetmemo.bio
DTSTAMP:20261121T005405Z
DTSTART;VALUE=DATE:20280515
DTEND;VALUE=DATE:20280516
SUMMARY:Aripiprazole (Abilify): Phase 2 readout est. (NCT07714213)
DESCRIPTION:Aripiprazole (Abilify)\, phase 2.\nStudy: Post-acute Infectious
  Syndrome - Aripiprazole Symptom Evaluation (PAIS-AriSE)\nEstimated primar
 y completion: 15 May 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/aripiprazole-abilify#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07714213
URL:https://assetmemo.bio/drug/aripiprazole-abilify#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07810738-9212@assetmemo.bio
DTSTAMP:20261121T005405Z
DTSTART;VALUE=DATE:20290315
DTEND;VALUE=DATE:20290316
SUMMARY:Aripiprazole (Abilify): Phase 2 readout est. (NCT07810738)
DESCRIPTION:Aripiprazole (Abilify)\, phase 2\, Major Depressive Disorder.\n
 Study: The BAARD Study : Evaluating a Computerized Approach to Treatment S
 election in Older Adults With Treatment Resistant Depression.\nEstimated p
 rimary completion: 15 March 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/aripiprazole-abilify#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07810738
URL:https://assetmemo.bio/drug/aripiprazole-abilify#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07483294-9212@assetmemo.bio
DTSTAMP:20261121T005405Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Aripiprazole (Abilify): Phase 4 readout est. (NCT07483294)
DESCRIPTION:Aripiprazole (Abilify)\, phase 4.\nStudy: Cerebellum-based Imag
 ing Neural Markers for Antipsychotic Response\nEstimated primary completio
 n: 1 December 2029. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/a
 ripiprazole-abilify#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07483294
URL:https://assetmemo.bio/drug/aripiprazole-abilify#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06433635-9212@assetmemo.bio
DTSTAMP:20261121T005405Z
DTSTART;VALUE=DATE:20300228
DTEND;VALUE=DATE:20300301
SUMMARY:Aripiprazole (Abilify): Phase 4 readout est. (NCT06433635)
DESCRIPTION:Aripiprazole (Abilify)\, phase 4\, Bipolar Disorder.\nStudy: Se
 quential Multiple Assignment Randomized Trial for Bipolar Depression\nEsti
 mated primary completion: 28 February 2030. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/aripiprazole-abilify#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06433635
URL:https://assetmemo.bio/drug/aripiprazole-abilify#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06969755-9212@assetmemo.bio
DTSTAMP:20261121T005405Z
DTSTART;VALUE=DATE:20300730
DTEND;VALUE=DATE:20300731
SUMMARY:Aripiprazole (Abilify): Phase 4 readout est. (NCT06969755)
DESCRIPTION:Aripiprazole (Abilify)\, phase 4\, Schizophrenia.\nStudy: Bioma
 rkers to Enhance Early Schizophrenia Treatment\nEstimated primary completi
 on: 30 July 2030. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ari
 piprazole-abilify#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06969755
URL:https://assetmemo.bio/drug/aripiprazole-abilify#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
